Following a positive profit alert, REMEGEN (09995) saw an increase of nearly 4%. As of the time of writing, the stock was up 3.68%, trading at HKD 87.3, with a turnover of HKD 6.0674 million. On January 30, REMEGEN issued an announcement stating that, based on preliminary calculations by the company's finance department, it expects total revenue for the 2025 fiscal year to be approximately RMB 3.25 billion. This represents an increase of about RMB 1.533 billion compared to the previous year, a surge of roughly 89%. The company anticipates achieving a net profit attributable to owners of the parent company of about RMB 716 million for the 2025 fiscal year, marking a significant turnaround from a loss to a profit compared to the same period last year. Furthermore, REMEGEN forecasts a net profit attributable to owners of the parent company, after deducting non-recurring gains and losses, of approximately RMB 78.5 million for 2025, also achieving a turnaround from loss to profitability year-on-year. The announcement highlighted that the domestic sales revenue of the company's core products, Telitacicept and Disitamab Vedotin, experienced rapid growth during the 2025 fiscal year, becoming the primary engines for performance growth. Concurrently, the company successfully secured a major collaboration, granting Vor Biopharma Inc. the exclusive global development and commercialization rights for Telitacicept outside the Greater China region, leading to a substantial increase in technology licensing revenue and shifting part of the overseas R&D expenses to the licensee. Additionally, through measures such as management optimization and iterative improvements in production processes, the company successfully reduced the unit production cost of its products, thereby enhancing product gross margin, while also achieving a notable decrease in the sales expense ratio. Integrating these multiple positive factors, the company's profitability efficiency improved significantly, and it is projected that the net profit for the 2025 fiscal year will achieve a turnaround from loss to profit.